https://newsletter.glp1studio.com/p/lilly-registers-two-eloratzp-obesityGLP-1 Studioen2026-10-20T17:00:00+00:00Lilly registers two EloraTZP obesity trials, results years awayhttps://newsletter.glp1studio.com/p/cagrisema-analysis-25-weight-lossGLP-1 Studioen2026-10-20T17:00:00+00:00CagriSema analysis: 25% weight loss in women at 68 weekshttps://newsletter.glp1studio.com/p/medicaid-glp-1-spending-swung-byGLP-1 Studioen2026-10-19T17:00:00+00:00Medicaid GLP-1 spending swung by state in Q1 2026https://newsletter.glp1studio.com/p/retatrutide-trial-219-weight-lossGLP-1 Studioen2026-10-19T17:00:00+00:00Retatrutide trial: 21.9% weight loss in higher-BMI group